Abstract Submission is Closed
Presentation Notifications will be sent in February 2018
Previous Presentation of Abstracts
Abstracts will be considered for presentation if they have NOT been previously published as an article at the TIME OF SUBMISSION.
- Abstracts must conform exactly to the instructions provided for electronic submission (by the American Transplant Congress). Abstracts must be submitted in English and all presentations will be in English. The abstract character limit is 2750 characters. This count includes characters and spaces in the following: Abstract Title, Abstract Body, Authors/Institutions, Table, and Figures.
- Abstracts accepted for oral or poster presentation will be published online in a supplement to the American Journal of Transplantation, the Joint Journal of the American Society of Transplant Surgeons and the American Society of Transplantation. Abstracts not accepted for presentation will not be published. Abstracts and program will also be posted prior to the meeting on the American Transplant Congress website. Please check this for official publication date.
- Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966:14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any transplant procedures performed must meet with the prevailing ethical standards.
Use of Animals
- All studies involving the use of animals must conform to the 1991 revision of "Guiding Principles in the Care and Use of Animals" (American Physiological Association).
Employees of Commercial Interests
- ATC recognizes that employees of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. In order to be compliant with the various continuing medical education regulatory bodies, abstracts submitted by employees of commercial interests should not include patient care recommendations. They should focus on the biology, physiology or physics and include content about the discovery process. Abstracts should avoid discussion of products, treatment or diagnostics. Abstracts from employees of commercial interests that are selected for oral or poster presentation will be subject to additional review prior to ATC.
- Ensure that all co-authors approve of the abstract submission, publication, and potential presentation.
- Abstracts will be blinded for peer review. Authors should be cautious in using institutional references in the body of the abstract. Do not put author names and/or affiliations in the body. Abstracts which include reference to authors or institutions will not be reviewed.
- The American Transplant Congress will grant a number of Travel Awards to assist young investigators to attend the joint meeting. The travel award is designed to help off set the expense to attend the meeting. Click Here for full award criteria.
Changes to Abstract
- You are able to edit your abstract until the submission deadline. After the submission deadline, only minor abstract changes (author or institution changes, disclosure, keyword or questionnaire updates) are allowed. Any corrections, withdrawals and/or changes will not be accepted after this date. Please note: the submission fee is final and non-refundable regardless of abstract edits or withdrawal.
Abstract Receipt Confirmation
- You will receive an email confirmation within two business days of submitting your abstract. If you submit on the deadline date and do not receive a confirmation within two business days, please contact CTI Meeting Technology Technical Support at: email@example.com or 1.217.398.1792.
Abstract Submission Fee
- A submission fee of $25 for ASTS and/or AST members (first OR last author) or $50 for non-members is required to submit each abstract. This fee is required at the time of submission and is accepted by online credit card payment only.
- ALL abstract authors are required to disclose any conflict of interest.
Abstract Clinical Content Validation
- All the recommendations involving clinical medicine in a activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in this activity in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
- Abstract content should not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME, or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients. Abstracts containing advocacy of unscientific modalities of diagnosis or therapy will not be considered.
In compliance with the Securities and Exchange Commission's Regulation FD (Fair Disclosure), the accepted abstracts are made available to the public on the ATC website in advance of the meeting. Thus, the first release of the abstracts is a public release. Coverage of additional research being presented at the annual meeting is under embargo until the date of presentation.
Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract. However, the ATC continues to require that information that goes beyond that contained within the abstract, e.g., discussion of the abstract done as part of a scientific presentation, is to be embargoed until the start of the scientific sessions. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Journalists failing to abide by the embargo may have their press credentials revoked.